Citi’s Geoff Meacham: Novo misses on Alzheimer’s trial, but ‘winners keep winning’ in obesity drugs

Geoff Meacham, Citi head of U.S. pharma and biotech research, joins CNBC’s ‘Money Movers’ to discuss his reaction to results from a drug trial Novo Nordisk, outlooks on the stock, and much more.